Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them,

专利摘要:
The present invention relates to novel proteins and their products from the MAGE group. Specifically, it relates to a MAGE protein fused to an immunological fusion partner such as lipoprotein D. Antigens of the invention can be formulated to provide a vaccine for the treatment of a wide range of tumors. Also provided are novel methods for purifying MAGE protein.
公开号:KR20010040675A
申请号:KR1020007008550
申请日:1999-02-02
公开日:2001-05-15
发明作者:테레사 카베존실바；조셉 코헨；몬세프 모하메드 슬라오우이；칼로타 비날스바쏠즈
申请人:장 스테판느；스미스클라인 비이참 바이오로지칼즈 에스.에이.；
IPC主号:

专利说明:

Tumor-ASSOCIATED ANTIGEN DERIVATIVES FROM THE MAGE FAMILY, AND NUCLEIC ACID SEQUENCES ENCODING THEM, USED FOR THE PREPARATION OF FUSION PROTEINS AND OF COMPOSITIONS FOR VACCINATION}
The present invention is directed to finding protein derivatives comprising tumor associated antigens and their usefulness in the treatment of cancer vaccines. Specifically, derivatives of the invention include antigens encoded by the group of MAGE genes (eg, MAGE-3, MAGE-1), for example from Haemophilus influenzae B. Fusion proteins linked to immunological fusion partners that provide T helper epitopes, such as lipidized forms of Protein D; Chemically modified MAGE proteins with reduced disulfide bridges of antigen and thus thiol blocking; And genetically modified MAGE proteins provided with an affinity tag and / or genetically modified to prevent disulfide bridge formation. Also described are methods for purification of MAGE protein and formulation of vaccines for the treatment of cancers including but not limited to melanoma, breast, bladder, lung, NSCLC, head and squamous cell carcinoma, colon carcinoma and esophageal carcinoma.
Antigens encoded by the group of MAGE genes include melanoma cells (including malignant melanoma) and some other cancers, including NSCLC (small cell lung cancer), head and neck squamous cell carcinoma, bladder transitional cell carcinoma and esophageal carcinoma. Predominantly expressed, but not detected in normal tissues except testes and placenta (Gaugler, 1994; Weynants, 1994; Patard, 1995). MAGE-3 is expressed in 69% of melanoma (Gaugler, 1994), also 44% in NSCLC (Yoshimatsu 1998), 48% in head and neck squamous cell carcinoma, 34% in bladder transitional cell carcinoma, 57% of esophageal carcinomas, 32% of colon carcinomas and 24% of breast cancers (cf. Van Pel, 1995; Inoue, 1995; Fujie, 1997; Nishimura 1997). Cancers that express MAGE protein are known as Mage related tumors.
Immunogenicity of human melanoma cells has been clearly demonstrated in experiments using a mixed culture of melanoma cells and autologous lymphocytes. This culture often produces specific cytotoxic T lymphocytes (CTLs) that can exclusively lyse autologous melanoma cells, but not autologous fibroblasts or autologous EBV modified B lymphocytes (Knuth, 1984; Anichini, 1987). Many of the antigens recognized on autologous melanoma cells by CTL clones have now been identified and they contain antigens from the MAGE group.
The first antigen that can be defined through recognition by specific CTL on autologous melanoma cells is MZ2-E (Van den Eynde, 1989), which is encoded in the gene MAGE-1 (Van der Bruggen, 1991). CTLs opposed to MZ2-E recognize and lyse autologous MZ2-E positive melanoma cells as well as other patients receiving cells with the HLA.A1 allele.
MAGE-1 gene is one of 12 closely related genes (MAGE 1, MAGE 2, MAGE3, MAGE 4, MAGE 5, MAGE 6, MAGE 7, MAGE 8, MAGE 9, MAGE 10, MAGE 11, MAGE 12) And are located on chromosome X and have 64% to 85% homology with each other in their coding sequence (De Plaen, 1994). These are often known as MAGE A1, MAGE A2, MAGE A3, MAGE A4, MAGE A5, MAGE A6, MAGE A7, MAGE A8, MAGE A9, MAGE A10, MAGE A11, MAGE A12 (MAGE A group). In addition, although less relevant, the other two groups of proteins are part of the MAGE group. These are the MAGE B and MAGE C groups. MAGE B group includes MAGE B1 (also known as MAGE Xp1, and DAM 10), MAGE B2 (also known as MAGE Xp2 and DAM 6), MAGE B3 and MAGE B4—MAGE C group is generally MAGE C1 and Contains the MAGE C2. In general, a MAGE protein can be defined by including a central sequence symbol located near the C-terminus of the protein (eg, for MAGE A1 309 amino acid protein, the central symbol corresponds to amino acids 195-279).
Thus, a common pattern of central symbols can be described as follows, where x represents a certain amino acid, lowercase residues are conserved (allowing for conservative changes), and uppercase residues are perfectly conserved. It is shown.
Central sequence symbol
LixvL (2x) I (3x) g (2x) apEExiWexl (2x) m (3-4x) Gxe (3-4x) gxp (2x) llt (3x) VqexYLxYxqVPxsxP (2x) yeFLWGprA (2x) Et93x) kv
Conservative substitutions are well known and generally set as default scoring matrices in sequence alignment computer programs. Such programs include PAM250 [Dayhoft M.O. et al., (1978), "A model of evolutinary changes in proteins", In "Atlas of Protein sequence and structure" 5 (3) M.O. Dayhoft (ed.), 345-352, National Biomedical Research Foundation, Washington, and Blosum 62, Steven Henikoft and Jorja G. Henikoft (1992), "Amino acid substitution matricies from protein blocks", Proc. Natl. Acad. Sci. USA 89 (Biochemistry): 10915-10919.
Generally, substitutions within the following groups are conservative substitutions, but substitutions between groups are considered non-conservative. This group is as follows:
i) aspartate / asparagine / glutamate / glutamine
ii) serine / threonine
iii) lysine / arginine
iv) phenylalanine / tyrosine / tryptophan
v) leucine / isoleucine / valine / methionine
vi) glycine / alanine
In the present invention and generally, the MAGE protein will be approximately 50% identical to amino acids 195 to 279 of MAGE A1 at the central site.
Several CTL epitopes have been identified in MAGE-3 protein. One such epitope, MAGE-3.A1, is a non-peptide sequence located between amino acids 168 and 176 of the MAGE-3 protein that constitutes an epitope specific for the CTL shown in connection with the MHC class I molecule HLA.A1. Recently two additional CTL epitopes have been identified on the peptide sequence of MAGE-3 protein by their ability to elicit a CTL response in a mixed culture of melanoma cells and autologous lymphocytes. These two epitopes have specific binding motifs for each of the HLA.A2 (Van der Bruggen, 1994) and HLA.B44 (Herman, 1996) alleles.
The present invention provides MAGE protein derivatives. This derivative is suitable for use in therapeutic vaccine formulations suitable for the treatment of a series of tumor types.
In one embodiment of the invention, the derivative is a fusion protein comprising an antigen from the group of MAGE proteins associated with a heterologous partner. This protein can be chemically conjugated, but the recombinant fusion protein is preferably expressed by allowing it to increase the level that can be produced in the expression system as compared to the non-fusion protein. Thus this fusion partner aids in providing T helper epitopes, preferably T helper epitopes that are recognized by humans (immunological fusion partners), or aids in the expression of proteins in higher yield than native recombinant proteins (expression amplification agents). )do. It will be desirable for the fusion partner to be both an immunological fusion partner and an expression amplification partner.
In a preferred form of the invention, the immunological fusion partner is derived from protein D, which is the surface protein of Gram-negative bacteria (Hemophilus influenza B) (WO91 / 18926). Protein D derivatives preferably comprise approximately the first third of the protein, in particular approximately N-terminal 100-110 amino acids. Protein D derivatives are preferably lipidated. The first 109 residues of the lipoprotein D fusion partner are included on the N-terminus providing a vaccine candidate antigen with additional exogenous T-cell epitopes and thus increase the expression level in E. coli (and thus also act as expression amplification agents). ). Lipid tails allow antigen presenting cells to optimally provide antigen.
Other fusion partners include NS1 (hemagglutinin), a nonstructural protein of influenza viruses. Different fragments can be used as long as they contain a T-helper epitope, but typically 81 N-terminal amino acids are used.
In another embodiment the immunological fusion partner is a protein known as LYTA. Preferably the C terminal portion of this molecule is used. Lyta is derived from Streptococcus pneumoniae, which is an autolysin, N-acetyl-L-alanine amidase, amidase that specifically cleaves certain bonds in the peptidoclycan backbone. Synthesize LYTA (encoded in lytA gene, Gene, 43 (1986) pages 265-272). The C-terminal domain of the LYTA protein contributes to the affinity for some choline analogs such as choline or DEAE. This feature was used to develop E. coli C-LYTA expressing plasmids useful for the expression of fusion proteins. Purification of hybrid proteins with C-LYTA fragments at the amino-terminus is known (Biotechnology: 10, (1992) page 795-798). As used herein, a preferred embodiment is to use the repeat site of a Lyta molecule found at the C terminus beginning at residue 178. Particularly preferred forms include residues 188-305.
The immunological fusion partner also has the advantage of helping with expression. In particular, such fusions are expressed in higher yield than native recombinant MAGE protein.
Our investigations have shown that in clinical settings such preparations can treat melanoma. In one case, patients with stage 4 melanoma disappeared after taking two lipo D 1/3 MAGE 3 His proteins without adjuvant.
Accordingly, the present invention provides fusion proteins comprising tumor associated antigens from the MAGE group associated with immunological fusion partners. Preferably the immunological fusion partner is Protein D or a fragment thereof, most preferably lipoprotein D. The MAGE protein is preferably MAGE A1 or MAGE A3. The lipoprotein D moiety preferably comprises the first 1/3 of lipoprotein D.
The protein of the present invention is preferably expressed in E. coli. In a preferred embodiment the protein is expressed with an affinity tag, for example a histidine tail comprising 5 to 9, preferably 6 histidine residues. They have the advantage of facilitating purification.
The present invention also provides nucleic acids encoding the proteins of the invention. These sequences can be inserted into appropriate expression vectors and used for DNA / RNA vaccination or expressed in a suitable host. Microbial vectors that express nucleic acids can be used as vaccines. For example, these vectors include poxviruses, adenoviruses, alphaviruses, listeria and monarphage.
DNA sequences encoding proteins of the invention are described in D.M Roberts et al. in Biochemistry 1985, 24, 5090-5098, by enzymatic binding, by chemical synthesis, by in vitro enzymatic polymerization, or by PCR techniques using, for example, heat stable polymerases. , Or by a combination of these techniques, using standard DNA synthesis techniques.
Enzymatic polymerisation of DNA is typically carried out in a suitable buffer containing nucleoside triphosphate dATP, dCTP, dGTP and dTTP as required at temperatures of 10 ° C. to 37 ° C. in volumes of up to 50 μl. DNA polymerase such as Klenow fragment can be performed in vitro. Enzymatic binding of DNA fragments is typically 0.05M Tris, pH 7.4, 0.01M MgCl ₂ , 0.01M Dithiothreitol, 1mM Spurmidine, 1mM ATP and 0.1mg / g at 4 ° C. to ambient temperature in volumes of 50 ml or less. ml DNA serum can be performed using an appropriate DNA binding enzyme such as T4 DNA binding enzyme in an appropriate buffer. Chemical synthesis of DNA polymers or fragments can be found in 'Chemical and Enzymatic Synthesis of Gene Fragments-A Laboratory Mannual' (ed.HG Gassen and A. Lang), Verlag Chemie, Weinheim (1982) or other scientific publications (eg For example, MJ Gait, HWD Matthes, M. Singh, BS Sproat, and RC Titmas, Nucleic Acids Research, 1982, 10, 6243; BS Sproat, and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5571; MD Matteucci and MH Caruthers, Tetrahedron Letters, 1980, 21, 719; MD Matteucci and MH Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; SP Adams et al., Journal of the American Chemical Society, 1983, 105, 661; Solid state technology as described in ND Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and HWD Matthes et al., EMBO Journal, 1984, 3, 801). It can be carried out by conventional phosphoester, phosphite or phosphoramidite chemistry.
Methods of the invention are described in Maniatis et al., Molecular Cloning-A Laboratory Manual; Cold Spring Harbor, 1982-1989].
Specifically, the method includes the following steps:
i) preparing a replicable or integratable expression vector capable of expressing in said host cell a DNA polymer comprising a nucleotide sequence encoding a protein or immunological derivative thereof;
ii) transforming a host cell with said vector;
iii) culturing the transformed host cell under conditions expressing the DNA polymer producing the protein; And
iv) recovering said protein.
As used herein, the term 'transformation' is used to mean the introduction of foreign DNA into a host cell. For example, this is described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwel Scientific Publications; Oxford, England, 1988] can be carried out by transformation, transduction or infection with an appropriate plasmid or viral vector using conventional techniques as described. Hereinafter, 'transformed' or 'transformer' refers to a host cell containing and expressing a foreign gene of interest.
Expression vectors are novel and form part of the present invention.
A replicable expression vector cleaves a vector suitable for the host cell according to the present invention to produce a linear DNA fragment with intact replicon and encodes a protein or derivative thereof of the invention under binding conditions. The linear fragment encoding the desired product, such as a DNA polymer, can be prepared by combining with one or more DNA molecules.
Thus, the DNA polymer can be preformed or formed during the preparation of the vector as desired.
The choice of vector will be determined in part by the host cell, which can be either prokaryotic or eukaryotic but is preferably E. coli or CHO cells. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses.
The preparation of replicable expression vectors can be traditionally carried out using the appropriate enzymes for restriction, polymerization and binding of DNA, for example by the methods described in Maniatis et al., Cited above. .
According to the present invention, recombinant host cells were prepared by transforming host cells using the replicable expression vector of the present invention under transformation conditions. Suitable transformation conditions are conventional and are described, for example, in Maniatis et al., Or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.
The choice of transformation conditions is determined by the host cell. Thus bacterial hosts such as E. coli are treated with CaCl ₂ solution or a solution comprising a mixture of RbC1, MnCl ₂ , potassium acetate and glycerol, followed by 3- [N-morpholino] -propane-sulfonic acid, RbC1 and glycerol Can be processed using Mammalian cells in culture can be transformed by calcium co-precipitation of vector DNA on the cells. The invention also encompasses host cells transformed with the replicable expression vector of the invention.
Culture of host cells transformed under conditions that allow expression of the DNA polymer has traditionally been described, for example, in Maniatis et al. and "DNA Cloning"]. Therefore, it is preferably cultured at less than 50 ℃ while supplying nutrients to the cells.
The product is recovered by conventional methods depending on the location of the host cell and expression product (secreted between cells or culture medium or cell periplasm). Thus, if the host cell is a bacterium such as Escherichia coli, it can be lysed for example physically, chemically or enzymatically and the protein product can be isolated from this lysate. If the host cell is a mammal, the product can generally be isolated from nutrient medium or cell free extracts. Traditional protein separation techniques include selective precipitation, adsorption chromatography, and affinity chromatography involving monoclonal antibody affinity columns.
Proteins of the invention are soluble both in liquid form or in lyophilized form.
In general, individual dosages are expected to include 1 μg to 1000 μg, preferably 30 μg to 300 μg of protein.
The present invention also provides a pharmaceutical composition comprising the protein of the present invention in a pharmaceutically acceptable excipient. Preferred vaccine compositions comprise at least lipoprotein D-MAGE-3. Such vaccines may optionally contain one or more tumor associated antigens. Examples include other members of the MAGE and GAGE groups. Other tumor-associated antigens suitable are MAGE-1, GAGE-1 or tyrosinase proteins.
Vaccine preparation is generally described in Vaccine Design "The subunit and adjuvant approach" (eds. Powell M.F. & Newman M.J). (1995) Plenum Press New York. Encapsulation into liposomes is described in Fullerton's patent (US Pat. No. 4,235,877).
Proteins of the invention preferably require adjuvants in the vaccine formulation of the invention. Suitable auxiliaries include aluminum salts such as aluminum hydroxide gels or aluminum phosphates, but may also be salts of calcium, iron or zinc, or insoluble suspensions of acylated tyrosine, or acylated sugars, cationic or anionic derivatives. Polysaccharides, or polyphosphazenes. Another known adjuvant is CpG comprising oligonucleotides. This oligonucleotide is characterized in that the CpG dinucleotide is not methylated. Such oligonucleotides are well known and are described, for example, in WO96 / 02555.
In the formulation of the invention, it is preferred that the adjuvant composition preferentially induces an immune response of type TH1. For example, suitable adjuvant systems include the combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) with aluminum salts. CpG oligonucleotides also preferentially induce a TH1 response.
An improved system involves the combination of monophosphoryl lipid A with saponin derivatives, in particular the combination of QS21 and 3D-MPL as found in WO 94/00153, or QS21 as found in WO 96/33739, quenched with cholesterol. ) It is related to the composition with low reaction induction.
Particularly effective adjuvant formulations containing QS21 3D-MPL and tocopherol in oil-in-water emulsions are described in WO 95/17210 and this is the preferred formulation.
Thus, in one embodiment of the present invention there is provided a vaccine containing lipoprotein D (or a derivative thereof)-MAGE-3 using a protein of the invention, more preferably monophosphoryl lipid A or a derivative thereof as an adjuvant do.
Preferably the vaccine further comprises saponin, more preferably QS21.
Preferably the formulation further comprises tocopherol in an oil-in-water emulsion. The present invention also provides a method of preparing a vaccine formulation comprising mixing a protein of the invention with a pharmaceutically acceptable excipient such as 3D-MPL.
In one aspect of the invention there is provided a method for purifying recombinantly produced MAGE-protein. This method is for example a strong chaotropic agent (eg, urea, guanidium hydrochloride), or an amphoteric detergent (eg, empigen BB-n-dodecyl-N, N-dimethyl Glycine), dissolving intra- and inter-protein molecular disulfide bridges, thereby blocking thiols to prevent oxidative recombination, and treating the protein with one or more chromatographic steps.
Preferably, the blocking agent is an alkylating agent. However, such blockers are not limited to alpha halo acids or alpha haloamides. For example, iodoacetic acid and iodoacetamide are the result of carboxymethylation or carboxyamidation (carbamidomethylation) of proteins. Other blockers may be used and described in The Proteins Vol II Eds H neurath, RL Hill and C-L Boeder, Academic press 1976, or Chemical Reagents for Protein modification Vol I eds. RL Lundblad and CM Noyes, CRC Press 1985. Typical examples of such other blocking agents include N-ethylmaleimide, chloroacetyl phosphate, O-methylisourea, acrylonitrile and the like. The use of a blocking agent has the advantage of preventing the agglomeration of the product to ensure stability for subsequent purification.
Blocking agents in embodiments of the invention are selected to induce stable covalent and irreversible derivatives (eg, alpha halo acids or alpha haloamides). However, other blockers may be selected such that after purification, the blocker can be removed to release uninduced protein.
MAGE proteins with derived free thiol residues are novel and form an aspect of the present invention. In particular, carboxyamidated or carboxymethylated derivatives are preferred embodiments of the present invention.
In a preferred embodiment of the invention the protein of the invention is provided with an affinity tag such as CLYTA or polyhistidine tail. In this case the protein after the blocking step is preferably subjected to affinity chromatography. For these proteins with polyhistidine tails, passivated metal ion affinity chromatography (IMAC) can be performed. The metal ion may be any suitable ion, for example zinc, nickel, iron, magnesium or copper, but is preferably zinc or nickel. Preferably the IMAC buffer contains an amphoteric detergent such as Empigen BB (hereinafter Empigen) which produces low levels of endotoxin in the final product.
If a protein with a Clyta moiety is produced, the protein can be purified by using its affinity for choline analogs such as choline or DEAE. In an embodiment of the invention the protein is provided with a polyhistidine tail and a cleta moiety. These can be purified by a simple two step affinity chromatography purification method.
The invention will be described in detail in the following examples:
Example I
Preparation of Recombinant E. Coli Strains Expressing Fusion Protein Lipoprotein D-MAGE-3-His (LPD 1 / 3-MAGE-3-His or LpD MAGE-3-His)
1.E. coli expression system
DNA encoding protein D was cloned into expression vector pMG 81 for production of lipoprotein D. This plasmid uses a signal derived from lambda phage DNA for transcription and translation of the inserted foreign gene. The vector contains two useful sites (NutL and NutR) to mitigate transcriptional polarity effects when given lambda PL promoter PL, operator OL and N protein (Gross et al., 1985. Mol. & Cell. Biol. 5: 1015). To stabilize the plasmid DNA, a vector with a PL promoter was introduced into the E. coli lytic host. The lysogenic host strain contains replication-defective lambda phage DNA integrated into the genome (Shatzman et al., 1983; In Experimental Manipulation of Gene Expression. Inouya (ed) pp 1-14. Academic Press NY). Lambda phage DNA directly synthesizes the cI inhibitor protein and binds to the OL inhibitor of the vector, thereby preventing the binding of the RNA polymerase to the PL promoter thereby preventing transcription of the inserted gene. The cI gene of the expression strain AR58 has a temperature sensitive mutation so that direct PL transcription can be regulated by temperature change, ie an increase in culture temperature inactivates the inhibitor and initiates the synthesis of foreign protein. This expression system allows for the control of the synthesis of foreign proteins, which may be particularly toxic to cells (Shimataka & Rosenberg, 1981. Nature 292: 128).
2. E. coli strain AR58
The AR58 soluble E. coli strain used for the production of LPD-MAGE-3-His protein is a derivative of the standard NIH E. coli K12 strain N99 (Fsu-galK2, LacZ-thr-). This strain contains defective tolerant lambda phage (galE :: TN10, 1 Kil-CI857 DH1). Kil-phenotypes prevent blocking of host macromolecular synthesis. cI857 mutations provide temperature sensitive damage to cI inhibitors. The DH1 deficiency removes the lambda phage right operon and host bio, uvr3 and chlA loci. AR58 strains were generated by transduction of N99 using P lambda phage conserved strains previously grown on SA500 derivatives (galE :: TN10, 1 Kil-cI857 DH1). Introduction of defective tolerant phage into N99 was selected using tetracycline by the presence of TN10 transposon encoding tetracycline resistance near the galE gene. N99 and SA500 are E. coli K12 strains derived from the laboratory of Dr. Martin Rosenberg of the National Institutes of Health.
3. Preparation of Vector Designed to Express Recombinant Protein LPD-MAGE-3-His
The principle of the present invention is a fusion partner linked to the N-terminus of MAGE-3, the sequence of N-terminal 1/3 of lipidated protein D and several histidine residues (His tail) located at its C-terminus. To express MAGE 3 as a fusion protein.
Protein D is a lipoprotein (42 kDa immunoglobulin D binding protein exposed to the surface of Gram-negative bacterial Haemophilus influenza). This protein is synthesized as a precursor with an 18 amino acid residue signal sequence and contains a consensus sequence for bacterial lipoproteins (WO 91/18926).
When the signal sequence of the lipoprotein is processed during release, Cys (located at position 19 in the precursor molecule) becomes an amino terminal residue and is modified simultaneously by covalent binding of ester- and fatty acid-binding fatty acids.
The fatty acid bound to the amino terminus cysteine residue then functions as a membrane anchor.
Plasmids expressing the fusion protein include 18 amino acid signal sequences and the first 109 residues of processed protein D, two unrelated amino acids (Met and Asp), amino acid residues 2 to 314 of MAGE-3 and the following seven It was designed to express precursor proteins comprising two Gly residues that function as hinge regions that expose His residues.
Thus, the recombinant strain produces a fusion protein having a processed lipidated His tail of 432 amino acid residues in length (see FIG. 1), which encodes the amino acid sequence described by ID 1 and the coding sequence described by ID 2. It is included.
4. Cloning method for the generation of LPD-MAGE-3-His fusion protein (vector pRIT14477)
CDNA plasmid containing the coding sequence for the MAGE-3 gene (from Dr. Thierry Boon of Ludwig Institute) [Gaugler B et al, 1994] and Lipo-D-1 / 3 A vector pRIT 14586 was used which contains the N-terminal portion of the coding sequence (prepared according to the schematic diagram in FIG. 2). The cloning method includes the following steps (see FIG. 3).
a) oligonucleotide sense: 5 'gc gcc atg gat ctg gaa cag cgt agt cag cac tgc aag cct and oligonucleotide antisense: 5' gcg tct aga tta atg gtg atg gtg atg gtg atg acc gcc ctc ttc ccc ctc tct caa PCR amplifying the sequences present in the plasmid cDNA MAGE 3; This amplification results in the following changes at the N terminus: change of the first 5 codons for E. coli codons, substitution of the Pro codon at the 1 position with an Asp codon, generation of an NcoI site at the 5 'end and finally 2 Addition of Gly codons and 7 His codons followed by addition of the XbaI site at the C-terminus.
b) cloning the amplified fragment into a TA cloning vector of Invitrogen to prepare intermediate vector pRIT 14647.
c) excision of the NcoI XbaI fragment from plasmid pRIT 14647 and cloning it into vector pRIT 14586.
d) transforming host strain AR58.
e) selecting and characterizing E. coli strain transformants containing plasmid pRIT 14477 to express the LPD-MAGE-3-His fusion protein.
Example II
Preparation of LPD1 / 3-MAGE-3-His Antigen
1. Growth and Induction of Bacterial Strains-Expression of LPD1 / 3-MAGE-3-His
AR58 cells transformed with plasmid pRIT 14477 were grown in 2 L flasks containing 400 ml of LY12 medium supplemented with yeast extract (6.4 g per liter) and kanamycin sulfate (50 mg per liter), respectively. A small amount of sample was taken from each flask for microscopy after incubation under shaking at 30 ° C. for 8 +/− 1 hour. The contents of the two flasks were mixed to provide an inoculum for a 20 L fermentor.
Inoculum (approximately 800 ml) was added to a 20 sterile (full volume) fermentor containing 7 L of medium and supplemented with 50 mg of kanamycin sulfate per liter. The pH was maintained at 6.8 by periodic addition of NH ₄ OH (25% v / v), and the temperature was maintained at 30 ° C. The air incorporation rate was maintained at 12 liters of air per minute and the dissolved oxygen pressure was maintained at 50% saturation by feedback control of the stirring speed. The overpressure in the fermenter was maintained at 500 g / cm ² (0.5 bar).
Feeding incubation was performed by controlling the addition of carbon feed solution. The feed solution was initially added at a rate of 0.04 ml per minute and exponentially increased for the first 42 hours to maintain a growth rate of 0.1 h ⁻¹ .
After 42 hours, the temperature of the fermenter is rapidly increased to 39 ° C. and the feed rate per minute during the induction phase for an additional 22 to 23 hours, ie for the time when the intracellular expression of LPD-MAGE-3-His reaches the maximum level. It was kept constant at 0.005 ml / g DCW.
Aliquots of culture (15 ml) were taken at regular intervals throughout the proliferation / induction phase and at the end of fermentation, the kinetics of microbial proliferation and intracellular product expression were studied and additional samples were provided for microbial identification / purity testing.
At the end of fermentation, the absorbance of the culture was 80-120 (corresponding to a cell concentration of 48-72 g DCW / L) and the total volume of the culture was approximately 12 liters. ECK32 cells were separated from the culture by rapidly cooling the culture to 6-10 ° C. and centrifuging at 5000 × g at 4 ° C. for 30 minutes. Concentrated ECK32 cells were quickly stored in plastic bags and immediately frozen at -80 ° C.
2. Extraction of Proteins
Frozen ECK32 enriched cells were thawed at 4 ° C. and then resuspended in cytolysis buffer to a final absorbance of 60 (corresponding to a cell concentration of about 36 g DCW / L).
The cells were digested by two passes through a high pressure homogenizer (1000 bar). The disrupted cell suspension was centrifuged (x 10000 g at 4 ° C. for 30 minutes) and the pellet fractions were washed with Triton X100 (1% w / v) and EDTA (1 mM) followed by phosphate buffered saline (PBS). Washed with a mixture of and Tween 20 (0.1% v / v) and finally with PBS. Between each wash step, the suspension was centrifuged at 4 ° C. × 10000 g for 30 minutes, the supernatant was discarded and the pellets were preserved.
Example III
Characterization of the Fusion Protein Lipo D-MAGE 3
1. Tablet
LPD-MAGE-3-His was purified from cell homogenates using the sequence of steps described below:
a) solubilizing the washed pellet fractions from cell destruction,
b) chemically reducing intra- and inter-protein disulfide bonds by blocking thiol groups to prevent oxidative recombination,
c) microfiltration of the reaction mixture to remove particulates and reduce endotoxins,
d) capturing and primary purification of LPD-MAGE-3-His by using affinity interactions between polyhistidine tail and zinc-loaded chelating Sepharose,
e) removing the impurity protein by anion exchange chromatography.
Purified LPD-MAGE-3-His was subjected to several polishing steps.
f) exchanging buffer and removing urea by size exclusion chromatography using Superdex 75,
g) filtration during the process,
h) buffer exchange and desalting by size exclusion chromatography using Sephadex G25.
Each of these steps is described in more detail below:
1.1) Solubilization of Cell Homogenizer Pellets
The pellet fraction from the final washing step (as described above) was redissolved in 800 ml of guanidine hydrochloride (6M) and sodium phosphate (0.1M, pH 7.0) overnight at 4 ° C.
1.2) Reduction and Carboxymethylation
The dissolved material (pale yellow, turbid suspension) was washed with argon to remove any residual oxygen, and 2-mercaptoethanol (14M) stock solution was added to give a final concentration of 4.3M (2-mercaptoethanol per ml of solution). 0.44 ml).
The resulting solution was divided into two glass flasks and heated to 95 ° C. in a thermostat. After 15 minutes of treatment at 95 ° C., the flask was removed from the thermostat and allowed to cool, where the contents were combined into a beaker (5 L) wrapped in one foil, allowed to stand on ice and solid iodoacetamide was added. Mixing was added vigorously to bring the final concentration to 6M (corresponding to 1.11 g of iodoacetamide per ml of solution). The mixture was allowed to stand on ice in the dark for 1 hour to completely solubilize iodoacetamide and finally by adding approximately 1 L of sodium hydroxide (5M) to neutralize (mixing vigorously and continuously monitoring pH). pH 7.5-7.8.
The resulting mixture was allowed to stand on ice in the dark for 30 minutes, after which the pH was adjusted back to pH 7.5-7.8.
1.3) Microfiltration
This mixed solution was subjected to a Minicross hollow fiber cartridge [reference number: M22M-600-01N; 5,600 cm ² , 0.2 μm] was microfiltered in an Amicon Proflux M12 tangential-flow apparatus. This permeate was preserved for subsequent chromatography purification.
1.4) Metal (Zn ²⁺ ) Chelate Chromatography (IMAC)
Metal chelate chromatography was performed in a BPG 100/500 column filled with chelating Sepharose FF (Pharmacia Biotechnology Cat.No. 17-0575-01) (Pharmacia Biotechnology Cat No. 18-1103-01). Was performed. The dimensions of the filled bed are: 10 cm in diameter; Cross section 79 cm ² ; Bed height 19 cm; The volume filled was 1500 ml. The empty column was sterilized with sodium hydroxide (0.5M) and then washed with purified water.
Support material (delivered in 20% v / v ethanol) was washed using purified water (8 L) on a Buchner funnel (under vacuum) and zinc was used by passing through at least 15 L of ZnCl ₂ (0.1 M) solution. Was charged. Excess zinc was removed by washing the support with 10 liters of purified water until the pH of the effluent reached the pH (pH 5.0) of the ZnCl ₂ solution. The support was then equilibrated with 4 liters of solution containing guanidine hydrochloride (6M) and sodium phosphate (0.1M, pH 7.0).
Permeate from microfiltration, containing LPD-MAGE-3-His, was mixed with the support material (batch binding) and a solution containing guanidine hydrochloride (6M) and sodium phosphate (0.1M, pH 7.0) was used. Was loaded into the BPG column and filled.
The next step in metallic chelate chromatography is to adjust the eluent flow rate to 60 ml per minute. After washing the column first using a solution containing guanidine hydrochloride (6M) and sodium phosphate (0.1M, pH 7.0), the urea (until until the column eluent reached zero absorbance at OD ₂₈₀ nm (reference)). 6M) and sodium phosphate (0.1M, pH 7.0).
A semipure LPD-MAGE-3-His protein fraction was eluted using a 2-fold column volume of a solution containing urea (6M), sodium phosphate (0.1M, pH 7.0) and imidazole (0.5M). The conductivity of this fraction was approximately 16 mS per cm.
1.5) Anion Exchange Chromatography
Prior to continuing anion exchange chromatography, the conductivity of the semi-pure LPD-MAGE-3-His protein fraction by dilution with a solution containing urea (6M) and Tris-HCl (20 mM, pH 8.0) was approximately cm Reduced to 4 mS per.
Anion exchange chromatography was performed on a BPG 200/500 column (Pharmaceutical Biotechnology Cat. No. 18-1103-11) filled with Q-Sepharose FF (Pharmaceutical Biotechnology, Cat. No. 17-0510-01). Was performed using. The dimensions of the filled bed are: 10 cm in diameter; Cross section 314 cm ² ; Bed height 9 cm; Filled volume is 2,900 ml.
The column was charged (using 20% v / v ethanol) and washed with 9 liters of purified water at an eluent flow rate of 70 ml per minute. The packed column was sterilized using 3 liters of sodium hydroxide (0.5M), washed with 30 liters of purified water and then equilibrated using 6 liters of solution containing urea (6M) and Tris-HCl (20 mM, pH 8.0). I was. Dilute, semi-purified LPD-MAGE-3-His was added to the column and the urea (6M), Tris-HCl (20 mM, pH 8.0), EDTA (1 mM) until the absorbance (280 nm) of the eluent dropped to zero. ) And 9 L of solution containing Tween (0.1%).
An additional wash step was performed using 6 liters of solution containing urea (6M) and Tris-HCl (20 mM, pH 8.0).
Purified LPD-MAGE-3-His was eluted from the column using a solution containing urea (6M), Tris-HCl (20 mM, pH 8.0) and NaCl (0.25 M).
1.6) Size Exclusion Chromatography
Removal of urea and buffer exchange from purified LPD-MAGE-3-His were both performed by size exclusion chromatography. This was done using an XK 50/100 column (Pharmacia Biotechnology Cat. No. 18-8753-01) filled with Superdex 75 (Pharmacia Biotechnology Cat. No. 17-1044-01). The dimensions of the filled bed are: 5 cm in diameter; Cross section 19.6 cm ² ; Bed height 90 cm; Filled volume is 1,800 ml.
The column was filled in ethanol (20%) and washed with 5 liters of purified water at a flow rate of 20 ml per minute. The column was sterilized using 2 liters of sodium hydroxide (0.5M), washed with 5 liters of purified water and then equilibrated with 5 liters of phosphate buffered saline containing Tween 80 (0.1% v / v).
Purified LPD-MAGE-3-His fraction (up to 500 ml per desalting test) was loaded onto the column at an eluent flow rate of 20 ml per minute. Desalted purified LPD-MAGE-3-His was eluted from the column using 3 liters of PBS containing Tween 80 (0.1% v / v).
Fractions containing LPD-MAGE-3-His eluted with the pore volume of the column.
1.7) In-process filtration
Bulk LPD-MAGE-3-His from size exclusion chromatography was filtered through a 0.22 μm membrane in a laminar flow hood (grade 10.000). The filtered bulk was frozen at −80 ° C. and stored until the desalting step.
1.8) Desalting Chromatography
Since the osmolality of the final bulk should be less than 400 mOsM, an additional buffer exchange step is required to reduce the salt concentration. This was followed by a desalting chromatography step using a BPG 100/950 column (Pharmacy Biotechnology Cat. No. 18-1103-03) filled with Sephadex G25 (Pharmacia Biotechnology Cat. No. 17-0033-02). Was performed. The dimensions of the filled bed are: 10 cm in diameter; Cross section 78.6 cm ² ; Bed height 85 cm; The filled volume is 6,500 ml.
Sephadex G25 was hydrated with 7 liters of purified water and expanded overnight at 4 ° C. The gel was then charged into the column with purified water at an eluent flow rate of 100 ml per minute.
The column was sterilized using 6 liters of sodium hydroxide (0.5M), followed by 10 liters of solution containing sodium phosphate (10 mM, pH 6.8), NaCl (20 mM) and Tween 80 (0.1% v / v). Equilibrated.
Purified LPD-MAGE-3-His fraction (up to 1500 ml per desalting test) was loaded onto the column at an eluent flow rate of 100 ml per minute. The desalted purified LPD-MAGE-3-His fraction was eluted with the pore volume of the column, sterile filtered through a 0.22 μm membrane and stored at -80 ° C.
The final bulk protein was thawed to + 4 ° C., aliquoted into vials and lyophilized in lactose excipient (3.2%).
2. Analysis on Coomassie-Stained SDS-Polyacrylamide Gel
LPD-MAGE-3-His purified antigen was analyzed by SDS-PAGE on 12.5% acrylamide gels under reducing conditions.
Protein load is 50 μg for Coomassie blue staining and 5 μg for silver nitrate staining. Clinical lot 96K19 and pilot lot 96J22 were analyzed. One major band appeared corresponding to a molecular weight of 60 kDa. Two small additional bands of approximately 45kDa and 35kDa also appeared.
3. Western Blot Analysis
Peptides identified by SDS-PAGE analysis of LPD-MAGE-3-His protein were identified by Western blot using mouse monoclonal antibody. These antibodies are those generated in tissue using a purified preparation of the MAGE-3-His protein (the protein does not contain the LPD portion of LPD-MAGE-3-His).
Two monoclonal antibody preparations (Mab 22 and Mab 54) were selected based on suitability for Western blot analysis and used for identification tests for lot release. 4 shows the band patterns obtained for lot 96K19 and lot 96J22 after staining with Mab 32 and Mab 54. FIG. 600 ng of protein was dissolved on 12.5% SDS-PAGE, transferred to nylon membrane, and visualized with anti-mouse antibody bound to peroxidase by reaction with Mab 32 and Mab 54 (60 μg per ml).
60 kDa peptide and 30 kDa peptide detected by SDS-PAGE were visualized by both Mab.
Example IV
1. Vaccine Preparation Using LPD-MAGE-3-His Protein
The vaccine used in this experiment is generated from recombinant DNA expressed in E. coli from strain AR58, encoding lipoprotein D 1 / 3-MAGE-3-His, with or without an adjuvant. As an adjuvant, the formulation comprises a mixture of 3 de-O-acylated monophosphoryl lipid A (3D-MPL) and QS21 in an oil-in-water emulsion. Adjuvant system SBA S2 is described above in WO 95/17210.
3D-MPL is an immunostimulator derived from lipopolysaccharide (LPS) of Gram-negative bacteria Salmonella minnesota. MPL was deacylated and the phosphate groups on lipid A residues were removed. This chemical treatment dramatically reduces toxicity while preserving immunostimulator properties (Rivi, 1986). Ribi Immunochemistry produced MPL and provided it to Smith Kline Beecham Biologicals. Experiments performed on Smith Klein Misery Biologics show that 3D-MPL combined with various carriers significantly improves both humoral cellular immunity and TH1 type cellular immunity.
Q21 is a natural saponin molecule extracted from the bark of South African tree Quillaja saponaria Molina. Purification techniques have been developed to separate individual saponins from the crude extracts of the bark, and specific saponins, QS21, have been isolated, which are triterpene glycosides that show stronger adjuvant activity and lower toxicity compared to the parent component. QS21 is known to activate MHC class I restricted CTLs for several subunit Ag as well as stimulate Ag specific lymphocyte proliferation (Kensil, 1992). Aquila (formerly Cambridge Biotech Corporation) produced QS21 and provided it to Smith Klein Micham Biologicals.
Experiments performed on Smith Klein Misery Biologics showed a clear synergistic effect of the combined use of MPL and QS21 in the induction of both humoral and immune responses of TH1 type cells.
Oil-in-water emulsions consist of an organic phase made from two oils (tocopherol and squalene) and an aqueous phase of PBS containing Tween 80 as an emulsifier. The emulsion contains 5% squalene, 5% tocopherol, 0.4% Tween 80 and has an average particle size of 180 nm and is known as SB62 (see WO 95/17210).
Experiments performed on Smith Klein Misery Biologics demonstrated that the aid of this O / W emulsion for 3D-MPL / QS21 (SBAS2) further increased later immunostimulatory to various subunit antigens.
2. Preparation of Emulsion SB62 (Twice Concentration)
Tween 80 was dissolved in phosphate buffered saline (PBS) to prepare a 2% solution in PBS. 5 g of DL alpha tocopherol and 5 ml of squalene were vortexed and thoroughly mixed to provide a 100 ml 2-fold emulsion. 90 ml of PBS / Tween solution was added and mixed thoroughly. This emulsion was then passed through a syringe and finally fluidized by using an M110S microfluidic machine. The oil droplets obtained were approximately 180 nm in size.
3. Preparation of Lipoprotein D 1/3-MAGE-3-His QS21 / 3D MPL in SBAS2 Formulation
Adjuvants were formulated as a combination of MPL and QS21 in an oil-in-water emulsion. This preparation was transferred to a 0.7 ml vial and mixed with lyophilized antigen (vial containing 30 μg to 300 μg antigen).
The composition of the dilution aid for the lyophilized vaccine is as follows:
The final vaccine was obtained by reconstituting the lyophilized LPD-MAGE-3-His preparation with adjuvant or PBS alone.
Adjuvant controls were prepared without antigen by replacing the protein by PBS.
4. Vaccine antigen: fusion protein lipoprotein D 1/3-MAGE-3-His
Lipoprotein D is a lipoprotein that is exposed to the surface of Gram-negative bacterial Haemophilus influenza.
Containing the first 109 residues of protein D processed as a fusion partner is to provide a vaccine antigen with T-cell epitopes. In addition to the LPD residues, the protein contains two unrelated amino acids (Met and Asp), amino acid residues 2 to 314 of Mage-3, and two Gly residues that serve as hinge regions that expose the subsequent seven His residues; have.
Example V
1. Immunogenicity of LPD-MAGE-3-His in Mice and Monkeys
To test the antigenicity and immunogenicity of human MAGE-3 protein, candidate vaccines were injected into two different mouse cell lines (C57BL / 6 and Balb / C) with differences in genetic background and MHC allele. For both mouse cell lines, potential MHC class-I and MHC class-II peptide motifs were theoretically predicted for the MAGE portion of the LPD-MAGE-3-His fusion protein.
a) immunization protocol
Five micrograms of LPD-MAGE-3-His, formulated / not formulated in SBAS2, were injected twice at the intervals of two weeks at the foot of five mice of each cell line at a tenth of the concentration used in the human setting.
b) proliferation assay
Lymphocytes were prepared by grinding spleen or popliteal lymph nodes from mice 2 weeks after the last injection. Place 2 x 10 ⁵ cells in a batch in a 96 well plate and place the cells in different concentrations (1-0.1 μg / ml) with or without coated His-Mage 3 on latex micro-beads And restimulated in vitro for 72 hours.
Compared to the lymphocyte proliferation response of mice injected with SBAS-2 formulation alone or PBS, increased MAGE-3 specific lymphocyte proliferation activity was injected with C57BL / 6 mice or Balb / C injected with LPD-MAGE-3-His protein. It was observed in both spleen cells (see FIGS. 5 and 7) and lymph node cells (see FIGS. 6 and 8) from mice.
In addition, higher proliferative responses were obtained using lymphocytes from mice immunized with LPD-MAGE-3-His in adjuvant SBAS2 (see FIGS. 6 and 8).
c) conclusion
LPD-MAGE-3-His is immunogenic in mice, and this immunogenicity can be increased by using SBAS2 adjuvant formulations.
2. Antibody Reactions
a) immunization protocol
Immunizing Balb / c mice or C57BL / 6 mice by injecting twice to the plantar at 2 week intervals using PBS, or SBAS2, or LPD-MAGE-3-His 5 μG, or LPD-MAGE-3-His + SBAS2 5 μG I was.
Three in the control group and five in the test group were used respectively.
b) indirect ELISA
Individual sera were taken after the second injection and used for indirect ELISA.
2 μG / ml of purified His MAGE 3 was used as coated antigen. After saturation in PBS + 1% neonatal calf serum for 1 hour at 37 ° C., the serum was serially diluted (starting with 1/1000) in saturation buffer and incubated overnight at 4 ° C. or for 90 minutes at 37 ° C. After washing in PBS / Tween 20,01%, biotinylated goat anti-mouse total IgG (1/1000) or goat anti-mouse IgG1, IgG2a, IgG2b antiserum (1/5000) was used as the second antibody It was. After 90 minutes of incubation at 37 ° C., streptavidin bound with peroxidase was added and TMB (tetra-methyl-benzidine peroxide) was used as substrate. After 10 minutes H ₂ SO ₄ 0.5M was added. The reaction was terminated by this to determine absorbance (OD).
c) results
9 compares the relative mean midpoint titers of serum from different groups of mice (N = 5 / group), which is the average dilution needed to reach the midpoint of flexion.
This result showed that the weak Ab response in both mouse cell lines tested increased after two injections of LPD-MAGE-3-His alone, but was higher when LPD-MAGE-3-His was injected in the presence of SBAS2. MAGE 3 Ab concentration is shown. Thus, two injections of LPD-MAGE-3-His + SBAS2 at two week intervals are sufficient to generate the observed high Ab response.
In addition, the Ab titer achieved in C57BL / 6 mice was higher after injection of LPD-MAGE-3-His + SBAS2 than after LPD-MAGE-3-His alone injection, but the response obtained in C57BL / 6 mice The higher Ab response observed in Balb / c mice when compared to can be explained by the difference in haplotype or background between these two strains.
Ig subgroup-specific anti-MAGE-3 responses after vaccination in different groups of mice can be seen in FIGS. 10 and 11, comparing the mean midpoint dilution of serum.
Neither IgA or IgM was detected in any serum samples from mice vaccinated with LPD-MAGE-3-His in adjuvant SBSA2.
In contrast, total IgG levels were slightly higher in serum from vaccinated mice using LPD-MAGE-3-His alone and significantly increased in the serum of animals injected with LPD-MAGE-3-His in SBAS2.
Because the levels of all IgG subgroups tested (IgG1, IgG2a, IgG2b) were higher in mice vaccinated with Ag with adjuvant than in mice injected with Ag or adjuvant alone, The analysis shows that mixed Ab responses were induced in mice.
However, since IgG1 and IgG2b were found predominantly in the sera of Balb / c mice and C57BL / 6 mice, respectively, the nature of this mixed Ab response after vaccination with LipoD-MAGE 3 in the presence of SBAS2 was observed in mouse cell lines. Seems to depend on.
3. Immunogenicity of Lipoprotein D 1/3 MAGE-3-His + SBAS2 Adjuvant in Rhesus Monkeys
Three groups of five rhesus macaques (Macaca Mulatta) were selected. RTS, S and gp120 were used as positive controls.
group:
County 1 Right Leg: RTS, S / SBAS2
Left leg: GP120 / SBAS2
County 2 Right Leg: RTS, S / SB26T
Left leg: GP120 / SB26T
County 3 Right Leg: Lipo D 1/3 MAGE 3 His / SABA2
Rhesus monkeys were vaccinated on day 0 and boosted on days 28 and 84 and blood was taken to determine their antibody response to both MAGE 3 and protein D components. The vaccine was administered intramuscularly by injection of a bolus (0.5 ml) at the back of the right leg.
Small amounts of blood samples were taken every 14 days. 3 ml of heparin-free blood sample was collected from the femoral vessels to allow coagulation for at least 1 hour and centrifuged at 2500 rpm for 10 minutes at room temperature.
Serum was removed, frozen at −20 ° C. and used for determination of antibody levels by specific ELISA.
96 well microplates (maxisorb Nunc) were coated overnight at 4 ° C. using His Mage 3 or Protein D. After 1 hour saturation at 37 ° C. with PBS NCS 1%, PBS Tween, anti rabbit biotinylated serum (see Amersham ref RPN 1004 lot 88) was added (1/5000) followed by serial dilution of rabbit serum Water was added at 37 ° C. for 1 hour 30 minutes (starting at 1/10). The plate was washed and peroxidase binding streptavidin (1/5000) was added at 37 ° C. for 30 minutes. After washing, 50 μl of TMB (BioRad) was added for 7 minutes and the reaction was terminated with 0.2 M H ₂ SO ₄ and drug excess was measured at 450 nm. Midpoint dilution was calculated by SoftmaxPro.
Antibody reactions
Small blood samples were taken every 14 days to examine the kinetics of the antibody response to MAGE 3 by ELISA. This result suggests that after a single injection of LPD 1/3 Mage 3 His + SBAS2, the Mage 3 specific total Ig titer was lowered, with an apparent increase in the second of Lipo D 1/3 Mage 3 + supplements in the same monkey. , 3 out of 5 animals following the third injection. Animals with a mild response remained negative after 3 injections. After 28 days of Post II or Post III, antibody titers returned to baseline levels. Subgroups of these antibodies were determined as predominant IgG and not IgM. Conversion to IgG suggests that the T helper response was triggered. The protein D specific antibody response, although weak, is exactly parallel to the Mage 3 antibody response.
Example VI
LPD-MAGE 1 His
LPD-MAGE 1-His was prepared in a similar manner. Amino acid and DNA sequences are described in SEQ ID NOs: 3 and 4. The obtained protein was purified in a similar manner to the LPD-MAGE-3-His protein. Briefly, cell cultures were homogenized and treated with 4 M guanidine HCl and 0.5 M beta mercaptoethanol in the presence of 0.5% empicen detergent. This product was filtered off and the permeate was treated with 0.6 M iodoacetamide. The carboxyamidated fractions were treated by IMAC (Zinc Chelate-Sepharose FF) chromatography. The column is first equilibrated and washed with a solution containing 4M guanidine, HCl, sodium phosphate (20 mM, pH 7.5) and 0.5% empigen, then the column is washed with 4M urea and 0.5 in sodium phosphate (20 mM, pH 7.5). Wash with a solution containing% empigen buffer. The protein was eluted in the same but with increased concentrations of imidazole (20 mM, 400 mM and 500 mM).
This eluate was diluted with 4M urea. The Q-Sepharose column was equilibrated and washed with 4M urea in 20 mM phosphate buffer (pH 7.5) in the presence of 0.5% empigen. A second wash was performed in the same but detergent free buffer. This protein was eluted in the same but with increased imidazole (150 mM, 400 mM, 1M). This eluate was ultrafiltered.
Example VII
Preparation of Expression Plasmid pRIT14426 and Transformation of Host Strain AR58 to Produce NS1-MAGE-3 His
Protein design
The design of the fusion protein NS1-MAGE-3-His for expression in E. coli is described in FIG. 12.
The primary structure of the obtained protein has the sequence described in ID5.
The coding sequence corresponding to the protein design (see ID 6) was subjected to the regulation of the λpL promoter in the E. coli expression plasmid.
Cloning Method for the Generation of NS1-MAGE-3-His Fusion Proteins
The starting material is a cDNA plasmid obtained from Dr. Thierry Boon of the Ludwig Institute, which contains the coding sequence for the MAGE-3 gene and the vector PMG81, and the vector PMG81 is the NS1 from influenza. Non-structural protein) containing 81 amino acids coding region.
The cloning method outlined in FIG. 13 includes the following steps:
a) oligonucleotide sense: 5 'gc gcc atg gat ctg gaa cag cgt agt cag cac tgc aag cct, and oligonucleotide antisense: 5' gcg tct aga tta atg gtg atg gtg atg gtg atg acc gcc ctc ttc ccc ctc tct caa PCR amplifying the sequences present in the plasmid cDNA MAGE-3.
This amplification results in the following changes at the N terminus: change of the first 5 codons for E. coli codons, substitution of the Pro codon at the 1 position with an Asp codon, generation of an NcoI site at the 5 'end and finally 2 Addition of Gly codons and 7 His codons followed by addition of the XbaI site at the C-terminus.
b) cloning the amplified fragment into a TA cloning vector from Invitrogen to prepare intermediate product vector pRIT14647
c) cutting the NcoI XbaI fragment from plasmid pRIT14647 and cloning it into vector pRIT PMG81
d) transforming host strain AR58
e) selecting and characterizing E. coli strain transformants containing plasmid pRIT14426 (see FIG. 14) expressing NS1-MAGE-3-His fusion protein
Characterization of Recombinant NS1-MAGE-3-His (pRIT14426)
Bacteria were grown in LB medium with 50 μg kanamycin per ml added at 30 ° C. When the culture reached OD = 0.3 (at 620 nm), heat induction was performed by raising the temperature to 42 ° C.
After 4 hours induction, cells were harvested, resuspended in PBS and lysed by pressing (degrading) for 3 hours in a French press. After centrifugation (60 min at 100,000 g), pellets, supernatants and whole extracts were analyzed by SDS-PAGE. The protein was visualized in a gel stained with Coomassie B1 with a fusion protein representing about 1% of the total E. coli protein. Recombinant protein appeared as a single band with an apparent molecular weight (MW) of 44.9 K. This fusion protein was identified by Western blot analysis using anti-NS1 monoclonal.
Example VIII
Purification of NS1-MAGE-3-His (E. coli) for rabbit / mouse immunization.
Tablet Overview:
The following purification scheme was used to purify antigens:
Cell Lysis + Centrifugation
↓
Antigen Solubilization + Centrifugation
↓
Ni ² + -NTA Agarose
↓
concentration
↓
Cell preparation
↓
TCA Precipitation and PBS Solubilization
a. Dissolution
Bacterial cells (23 g) were dissolved in 203 ml of 50 mM PO ₄ pH7 buffer by Rannie (homogenizer) and the lysates were centrifuged in a JA20 rotor at 15,000 rpm for 30 minutes.
The supernatant was removed.
b. Antigen solubilization
One third of the pellet was resolubilized overnight at 4 ° C. in 34 ml of 100 mM PO 4-6 M GuHC1 pH 7. After centrifugation in a JA20 rotor for 30 minutes at 15,000 rpm, the pellets were removed and the supernatant was further purified by IMAC.
c. Affinity Chromatography: Ni ² + -NTA Agarose (Qiagen)
Column volume: 15 ml (16 mm x 7.5 cm)
Fill Buffer: 0.1M PO ₄ -6M GuHC1 pH7
Sample buffer: homology
Wash buffer: 0.1M PO ₄ -6M GuHC1 pH7
0.1M PO ₄ -6M Urea pH7
Elution: imidazole gradient (0 → 250 mM) in 0.1 M PO ₄ buffer (pH 7) with 6 M urea.
Flow rate: 2 ml per minute
a. concentration:
Antigen positive fractions in IMAC eluate (160 ml) were combined and concentrated to 5 ml in Amicon stirred cells on a Filtron membrane (type Omega cut-off 10,000).
b. Manufacturing Electrophoresis (Prep Cell Biorad)
2.4 ml of concentrated sample was boiled in 0.8 ml of reducing sample buffer and loaded on 10% acrylamide gel. Antigen was eluted in tris-glycine buffer (pH 8.3) with 4% SDS and the NS1-MAGE 3 His positive fractions were combined.
a. TCA precipitation:
Antigen was precipitated by TCA and centrifuged in a JA20 rotor at 15,000 rpm for 20 minutes, after which the supernatant was removed. The pellet was redissolved in PBS buffer pH 7.4.
This protein is soluble in PBS after freezing / thawing and showed no degradation when stored at 37 ° C. for 3 hours and has an apparent molecular weight of approximately 50,000 Daltons as determined by SDS (12.5% PAGE).
Example IX
Preparation of Escherichia Coli Strains Expressing the Fusion Protein CLYTA-MAGE-1-His Tail
1. Preparation of Expression Plasmid pRIT14613 and Transformation of Host Strain AR58:
Protein design:
The design of the fusion protein Clyta-Mage-1-His for expression in E. coli is described in FIG. 15.
The primary structure of the obtained protein has the sequence set forth in SEQ ID NO: 7.
The coding sequence corresponding to the protein design (see SEQ ID NO: 8) was subjected to the regulation of the λpL promoter in the E. coli expression plasmid.
Cloning:
Starting materials are the vector PCUZ1 and the vector pRIT14518, which contain 117 C-terminal codons of the LytA coating region from Streptococcus pneumoniae, in which we obtained from Dr. Thierry Boone of the Ludwig Institute The MAGE-1 gene cDNAs from the plasmids were subcloned beforehand.
The cloning method (see FIG. 16) for the expression of CLYTA-Mage-1-His protein comprises the following steps:
2. Preparation of CLYTA-Mage-1-His Coding Sequence Module:
a) The first step is to attach the NdeI-AflIII restriction site to the side of the CLYTA sequence as PCR amplification. PCR amplification uses plasmid PCUZ1 as template and oligonucleotide sense as primer: 5 'tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac, and oligonucleotide antisense: 5' GCC AGA CAT GTC CAA TTC TGG CCT GTC TGC CAG was performed. This resulted in amplification with a CLYTA sequence of 378 nucleotides in length.
b) The second step is to link the CLYTA sequence with the MAGE-1-His sequence to generate the coding sequence for the fusion protein. This step involves excision of the NdeI-AflIII Clyta fragment, insertion into the vector pRIT14518 previously opened by NdeI and NcoI (NcoI and aflIII compatibility) restriction enzymes, resulting in plasmid pRIT14613.
c) The third step is transforming host strain AR58.
d) The fourth step is to select and characterize E. coli transformants (KAN resistance) containing plasmid pRIT14613 (see FIG. 16).
1. Characterization of the recombinant protein CLYTA-MAGE-1-His (pRIT14613):
Bacteria were grown in LB medium with 50 μg kanamycin per ml added at 30 ° C. When the culture reached OD = 0.3 (at 620 nm), heat induction was performed by raising the temperature to 38 ° C.
After 4 hours induction, cells were harvested and resuspended in PBS and lysed by one shot (by digesting). After centrifugation, the pellets, supernatants and whole extracts were analyzed by SDS-PAGE. The protein was visualized on Coomassie B1 stained gel, where the fusion protein was found to be about 1% of the total E. coli protein. The recombinant protein apparently appeared as a single band with an MW of about 49 kD. Identification was by Western blot analysis using anti-Mage-1 polyclonal antibody.
Reconstruction of the expression unit consisting of the long λpL promoter (useful for nalidixic acid induction) and the CLYTA-Mage-1 coding sequence pRIT14614:
EcoRI-NcoI restriction fragments comprising a long PL promoter and part of the CLYTA sequence were prepared from plasmid pRIT DVA6 and inserted between the EcoRI-NcoI sites of plasmid pRIT14613.
Recombinant plasmid pRIT14614 was obtained.
E. coli AR120 was transformed using the recombinant plasmid pRIT14614 (see FIG. 17) encoding the fusion protein CLYTA-Mage-1-His. Kan resistant candidate strains were selected and characterized.
Characterization of Recombinant Proteins:
Bacteria were grown in LB medium with 50 mg of kanamycin added per ml at 30 ° C. When the culture reached OD = 400 (at 620 nm), nalidix acid was added to bring the final concentration to 60 mg per ml.
After 4 hours induction, cells were harvested and resuspended in PBS and lysed by digestion (degraded CLS “one shot” type). After centrifugation, the pellets, supernatants and whole extracts were analyzed by SDS-PAGE. Proteins were visualized on Coomassie blue stained gels, where fusion proteins represented about 1% of the total E. coli protein. Fusion proteins were identified by Western blot analysis using rabbit anti-Mage-1 polyclonal antibodies. Recombinant protein appeared as a single band with an apparent molecular weight of about 49 kD.
Example X
CLYTA-MAGE-3-HIS
A: Tumor-Retarding Recombinant Antigen: The fusion protein CLYTA-Mage-3-His, in which the C-lyt A fusion partner leads the expression of soluble proteins, serves as an affinity tag and provides a useful T-helper.
Preparation of Escherichia Coli Strains Expressing the Fusion Protein CLYTA-Mage-3-His Tail
Preparation of the Expression Plasmid pRIT14646 and Transformation of Host Strain AR120:
Protein design:
The design of the fusion protein Clyta-Mage-3-His expressed in E. coli is described in FIG. 18.
The primary structure of the obtained protein has the sequence set forth in SEQ ID NO: 9 and the coding sequence in SEQ ID NO: 10.
The coding sequence corresponding to this protein design was subjected to the control of the λpL promoter in the E. coli expression plasmid.
Cloning:
Starting materials include the vector PCUZ1 and the vector pRIT14426 containing 117 C-terminal codons of the Lyt A coding region from Streptococcus pneumoniae as described in Gene 43, (1986) p.265-272. Here, we previously subcloned the MAGE-3 gene cDNA from a plasmid obtained from Dr. Thierry Boun of the Ludwig Institute.
The cloning method (see FIG. 19) for the expression of CLYTA-MAGE-3-His protein comprises the following steps:
1. Preparation of CLYTA-MAGE-3-His Coding Sequence Module:
1.1. The first step is PCR amplification, to attach AflII and AflIII restriction sites to the sides of the CLYTA sequence. PCR amplification using plasmid PCUZ1 as template and oligonucleotide sense as primer: 5 'tta aac cac acc tta agg agg ata taa cat atg aaa ggg gga att gta cat tca gac, and oligonucleotide antisense: 5' ccc aca tgt cca gac tgc tgg cca att ctg gcc tgt ctg cca gtg. The result was amplified with a CLYTA sequence of 427 nucleotides in length. The amplified fragment was cloned into Invitrogen's TA cloning vector to obtain intermediate product vector pRIT14661.
1.2. The second step is to link the CLYTA sequence with the MAGE-3-His sequence to generate the coding sequence for the fusion protein. This step involves excision of the Afl II-Afl-III Clyta fragment and insertion into the vector pRIT14426 previously opened by Afl II and NcoI (NcoI and AflII compatibility) restriction enzymes, resulting in plasmid pRIT14662.
2. Reconstitution of the expression unit consisting of the long λpL promoter (useful for nalidixic acid induction) and the CLYTA-Mage-3 coding sequence:
A BglII-XbaI restriction fragment comprising a short pL promoter and a CLYTA-Mage-3-His coding sequence was prepared from plasmid pRIT14662 to obtain plasmid TCM67 (a derivative of pBR322, which is resistant to ampicillin and contains a long λpL promoter. Between the BglII-XbaI sites of PCT / EP92 / O1827). Plasmid pRIT14607 was obtained.
E. coli AR120 was transformed using the recombinant plasmid pRIT14607 encoding the fusion protein Clyta-Mage-3 His [Mott et al. 1985, Proc. Natl. Acad. Sci, 82: 88]. Ampicillin resistant candidate strains were selected and characterized.
3. Preparation of Plasmid pRIT14646:
Finally, a plasmid similar to pRIT14607 but with kanamycin selectivity was prepared (pRIT14646).
Characterization of Recombinant Proteins:
The bacteria were grown in LB medium with 50 mg of kanamycin added per ml at 30 ° C. When the culture reached OD = 400 (at 600 nm) nalidix acid was added to bring the final concentration to 60-g per ml.
After 4 hours induction, cells were harvested and resuspended in PBS and lysed by digestion (degraded CLS “one shot” type). After centrifugation, the pellets, supernatants and whole extracts were analyzed by SDS-PAGE. Proteins were visualized on Coomassie blue stained gels, where fusion proteins represented about 1% of the total E. coli protein. This fusion protein was identified by Western blot analysis using rabbit anti-Mage-3 polyclonal antibody. Recombinant protein appeared as a single band with an apparent MW of about 58 kD.
Example XI
Preparation of the recombinant protein CLYTA-Mage-3 His:
Recombinant bacterium AR120 (pRIT14646) was grown in a 20 L fermentor under fed-batch conditions at 30 ° C. Nalidix acid was added to induce expression of the recombinant protein by bringing the final concentration to 60 g per ml. At the end of fermentation, cells were harvested and lysed at 60 OD / 600 by two passes through a French press mill (20000 psi). Lysed cells were pelleted at 15000 g at 4 ° C. for 20 minutes. The supernatant containing the recombinant protein was loaded onto exchange DEAE Sepharose CL6B resin (Pharmacia) previously equilibrated in 0.3 M NaCl, 20 mM Tris HCl pH 7.6 buffer A. After washing the column with buffer A, the fusion protein was eluted with 2% choline in buffer A. Positive antigen fractions were combined as revealed by Western blotting assay using anti-Mage-3 antibody. DEAE-eluted antigen was treated with 0.5% Empigen BB (amphoteric detergent) and 0.5M NaCl, and ionic metal affinity pre-equilibrated in 0.5% Empigen BB, 0.5M NaCl, 50 mM phosphate buffer pH 7.6 (Buffer B) It was loaded onto a degree chromatography column.
The IMAC column was washed using buffer B until the 280 nm absorbance reached baseline. Antigens were eluted with imidazole gradient 0-250 mM imidazole in buffer C after a second wash in buffer B without empgen BB (buffer C) to remove the detergent.
The 0.090-0.250 M imidazole fractions were combined, concentrated on a 10 kDa Pitron Omega membrane and dialyzed against PBS buffer.
conclusion:
We have demonstrated that the fused protein LPD-MAGE3-His is immunogenic in mice and that this immunogenicity (proliferative response and antibody response) can be further increased by using the adjuvant described above. Purification can be enhanced by inducing thiols to form disulfide bonds.
We also demonstrated that higher antibody responses can be triggered by vaccination with LPD-MAGE-3-His in the presence of adjuvants. The predominant isotype found in serum of C57BL / 6 is IgG2b, suggesting an increased TH1 type immune response.
In humans, the clinical setting of treating patients with LPD-MAGE3-His in formulations without a modulator eliminated melanoma.
SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: SmithKline Beecham Biologicals
(ii) title of the side: vaccine
(iii) NUMBER OF SEQUENCES: 10
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SmithKline Beecham
(B) STREET: 2 New Horizons Court, Great West Road, B
(C) CITY: Middx
(D) STATE:
(E) COUNTRY: UK
(F) ZIP: TW8 9EP
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY / AGENT INFORMATION:
(A) NAME: Dalton, Marcus J
(B) REGISTRATION NUMBER:
(C) REFERENCE / DOCKET NUMBER: B45126
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 0181 9756348
(B) TELEFAX: 0181 9756177
(C) TELEX:
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 452 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Met Asp Pro Lys Thr Leu Ala Leu Ser Leu Leu Ala Ala Gly Val Leu
1 5 10 15
Ala Gly Cys Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys
20 25 30
Ser Asp Lys Ile Ile Ile Ala His Arg Gly Ala Ser Gly Tyr Leu Pro
35 40 45
Glu His Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp
50 55 60
Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val
65 70 75 80
Ile His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe
85 90 95
Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val Ile Asp Phe Thr
100 105 110
Leu Lys Glu Ile Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met
115 120 125
Asp Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Gly Leu Glu
130 135 140
Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala Thr
145 150 155 160
Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val Glu Val Thr
165 170 175
Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro Gln Ser Pro
180 185 190
Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro Leu Trp Ser
195 200 205
Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly Pro Ser Thr
210 215 220
Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser Arg Lys Val
225 230 235 240
Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala Arg Glu Pro
245 250 255
Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn Trp Gln Tyr
260 265 270
Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu Val
275 280 285
Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu Tyr Ile
290 295 300
Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asn
305 310 315 320
Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu Ala Ile Ile
325 330 335
Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu Leu
340 345 350
Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile Leu Gly Asp
355 360 365
Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn Tyr Leu Glu
370 375 380
Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu Trp
385 390 395 400
Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val Leu His His
405 410 415
Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro Pro Leu His
420 425 430
Glu Trp Val Leu Arg Glu Gly Glu Glu Thr Ser Gly Gly His His His
435 440 445
His His His
450
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1353 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
ATGGATCCAA AAACTTTAGC CCTTTCTTTA TTAGCAGCTG GCGTACTAGC AGGTTGTAGC 60
AGCCATTCAT CAAATATGGC GAATACCCAA ATGAAATCAG ACAAAATCAT TATTGCTCAC 120
CGTGGTGCTA GCGGTTATTT ACCAGAGCAT ACGTTAGAAT CTAAAGCACT TGCGTTTGCA 180
CAACAGGCTG ATTATTTAGA GCAAGATTTA GCAATGACTA AGGATGGTCG TTTAGTGGTT 240
ATTCACGATC ACTTTTTAGA TGGCTTGACT GATGTTGCGA AAAAATTCCC ACATCGTCAT 300
CGTAAAGATG GCCGTTACTA TGTCATCGAC TTTACCTTAA AAGAAATTCA AAGTTTAGAA 360
ATGACAGAAA ACTTTGAAAC CATGGATCTG GAACAGCGTA GTCAGCACTG CAAGCCTGAA 420
GAAGGCCTTG AGGCCCGAGG AGAGGCCCTG GGCCTGGTGG GTGCGCAGGC TCCTGCTACT 480
GAGGAGCAGG AGGCTGCCTC CTCCTCTTCT ACTCTAGTTG AAGTCACCCT GGGGGAGGTG 540
CCTGCTGCCG AGTCACCAGA TCCTCCCCAG AGTCCTCAGG GAGCCTCCAG CCTCCCCACT 600
ACCATGAACT ACCCTCTCTG GAGCCAATCC TATGAGGACT CCAGCAACCA AGAAGAGGAG 660
GGGCCAAGCA CCTTCCCTGA CCTGGAGTCC GAGTTCCAAG CAGCACTCAG TAGGAAGGTG 720
GCCGAATTGG TTCATTTTCT GCTCCTCAAG TATCGAGCCA GGGAGCCGGT CACAAAGGCA 780
GAAATGCTGG GGAGTGTCGT CGGAAATTGG CAGTATTTCT TTCCTGTGAT CTTCAGCAAA 840
GCTTCCAGTT CCTTGCAGCT GGTCTTTGGC ATCGAGCTGA TGGAAGTGGA CCCCATCGGC 900
CACTTGTACA TCTTTGCCAC CTGCCTGGGC CTCTCCTACG ATGGCCTGCT GGGTGACAAT 960
CAGATCATGC CCAAGGCAGG CCTCCTGATA ATCGTCCTGG CCATAATCGC AAGAGAGGGC 1020
GACTGTGCCC CTGAGGAGAA AATCTGGGAG GAGCTGAGTG TGTTAGAGGT GTTTGAGGGG 1080
AGGGAAGACA GTATCTTGGG GGATCCCAAG AAGCTGCTCA CCCAACATTT CGTGCAGGAA 1140
AACTACCTGG AGTACCGGCA GGTCCCCGGC AGTGATCCTG CATGTTATGA ATTCCTGTGG 1200
GGTCCAAGGG CCCTCGTTGA AACCAGCTAT GTGAAAGTCC TGCACCATAT GGTAAAGATC 1260
AGTGGAGGAC CTCACATTTC CTACCCACCC CTGCATGAGT GGGTTTTGAG AGAGGGGGAA 1320
GAGGGCGGTC ATCACCATCA CCATCACCAT TAA 1353
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1341 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
ATGGATCCAA AAACTTTAGC CCTTTCTTTA TTAGCAGCTG GCGTACTAGC AGGTTGTAGC 60
AGCCATTCAT CAAATATGGC GAATACCCAA ATGAAATCAG ACAAAATCAT TATTGCTCAC 120
CGTGGTGCTA GCGGTTATTT ACCAGAGCAT ACGTTAGAAT CTAAAGCACT TGCGTTTGCA 180
CAACAGGCTG ATTATTTAGA GCAAGATTTA GCAATGACTA AGGATGGTCG TTTAGTGGTT 240
ATTCACGATC ACTTTTTAGA TGGCTTGACT GATGTTGCGA AAAAATTCCC ACATCGTCAT 300
CGTAAAGATG GCCGTTACTA TGTCATCGAC TTTACCTTAA AAGAAATTCA AAGTTTAGAA 360
ATGACAGAAA ACTTTGAAAC CATGGGCTCT CTGGAACAGC GTAGTCTGCA CTGCAAGCCT 420
GAGGAAGCCC TTGAGGCCCA ACAAGAGGCC CTGGGCCTGG TGTGTGTGCA GGCTGCCACC 480
TCCTCCTCCT CTCCTCTGGT CCTGGGCACC CTGGAGGAGG TGCCCACTGC TGGGTCAACA 540
GATCCTCCCC AGAGTCCTCA GGGAGCCTCC GCCTTTCCCA CTACCATCAA CTTCACTCGA 600
CAGAGGCAAC CCAGTGAGGG TTCCAGCAGC CGTGAAGAGG AGGGGCCAAG CACCTCTTGT 660
ATCCTGGAGT CCTTGTTCCG AGCAGTAATC ACTAAGAAGG TGGCTGATTT GGTTGGTTTT 720
CTGCTCCTCA AATATCGAGC CAGGGAGCCA GTCACAAAGG CAGAAATGCT GGAGAGTGTC 780
ATCAAAAATT ACAAGCACTG TTTTCCTGAG ATCTTCGGCA AAGCCTCTGA GTCCTTGCAG 840
CTGGTCTTTG GCATTGACGT GAAGGAAGCA GACCCCACCG GCCACTCCTA TGTCCTTGTC 900
ACCTGCCTAG GTCTCTCCTA TGATGGCCTG CTGGGTGATA ATCAGATCAT GCCCAAGACA 960
GGCTTCCTGA TAATTGTCCT GGTCATGATT GCAATGGAGG GCGGCCATGC TCCTGAGGAG 1020
GAAATCTGGG AGGAGCTGAG TGTGATGGAG GTGTATGATG GGAGGGAGCA CAGTGCCTAT 1080
GGGGAGCCCA GGAAGCTGCT CACCCAAGAT TTGGTGCAGG AAAAGTACCT GGAGTACCGG 1140
CAGGTGCCGG ACAGTGATCC CGCACGCTAT GAGTTCCTGT GGGGTCCAAG GGCCCTCGCT 1200
GAAACCAGCT ATGTGAAAGT CCTTGAGTAT GTGATCAAGG TCAGTGCAAG AGTTCGCTTT 1260
TTCTTCCCAT CCCTGCGTGA AGCAGCTTTG AGAGAGGAGG AAGAGGGAGT CGGCGGTCAT 1320
CACCATCACC ATCACCATTA A 1341
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 466 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Met Asp Pro Lys Thr Leu Ala Leu Ser Leu Leu Ala Ala Gly Val Leu
1 5 10 15
Ala Gly Cys Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys
20 25 30
Ser Asp Lys Ile Ile Ile Ala His Arg Gly Ala Ser Gly Tyr Leu Pro
35 40 45
Glu His Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp
50 55 60
Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val
65 70 75 80
Ile His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe
85 90 95
Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val Ile Asp Phe Thr
100 105 110
Leu Lys Glu Ile Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met
115 120 125
Gly Ser Leu Glu Gln Arg Ser Leu His Cys Lys Pro Glu Glu Ala Leu
130 135 140
Glu Ala Gln Gln Glu Ala Leu Gly Leu Val Cys Val Gln Ala Ala Thr
145 150 155 160
Ser Ser Ser Ser Pro Leu Val Leu Gly Thr Leu Glu Glu Val Pro Thr
165 170 175
Ala Gly Ser Thr Asp Pro Pro Gln Ser Pro Gln Gly Ala Ser Ala Phe
180 185 190
Pro Thr Thr Ile Asn Phe Thr Arg Gln Arg Gln Pro Ser Glu Gly Ser
195 200 205
Ser Ser Arg Glu Glu Glu Gly Pro Ser Thr Ser Cys Ile Leu Glu Ser
210 215 220
Leu Phe Arg Ala Val Ile Thr Lys Lys Val Ala Asp Leu Val Gly Phe
225 230 235 240
Leu Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu Met
245 250 255
Leu Glu Ser Val Ile Lys Asn Tyr Lys His Cys Phe Pro Glu Ile Phe
260 265 270
Gly Lys Ala Ser Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys
275 280 285
Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly
290 295 300
Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asn Gln Ile Met Pro Lys Thr
305 310 315 320
Gly Phe Leu Ile Ile Val Leu Val Met Ile Ala Met Glu Gly Gly His
325 330 335
Ala Pro Glu Glu Glu Ile Trp Glu Glu Leu Ser Val Met Glu Val Tyr
340 345 350
Asp Gly Arg Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr
355 360 365
Gln Asp Leu Val Gln Glu Lys Tyr Leu Glu Tyr Arg Gln Val Pro Asp
370 375 380
Ser Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala Leu Ala
385 390 395 400
Glu Thr Ser Tyr Val Lys Val Leu Glu Tyr Val Ile Lys Val Ser Ala
405 410 415
Arg Val Arg Phe Phe Phe Pro Ser Leu Arg Glu Ala Ala Leu Arg Glu
420 425 430
Glu Glu Glu Gly Val Gly Gly His His His His His His His
435 440 445
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 404 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Met Asp Pro Asn Thr Val Ser Ser Phe Gln Val Asp Cys Phe Leu Trp
1 5 10 15
His Val Arg Lys Arg Val Ala Asp Gln Glu Leu Gly Asp Ala Pro Phe
20 25 30
Leu Asp Arg Leu Arg Arg Asp Gln Lys Ser Leu Arg Gly Arg Gly Ser
35 40 45
Thr Leu Gly Leu Asp Ile Glu Thr Ala Thr Arg Ala Gly Lys Gln Ile
50 55 60
Val Glu Arg Ile Leu Lys Glu Glu Ser Asp Glu Ala Leu Lys Met Thr
65 70 75 80
Met Asp Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Gly Leu
85 90 95
Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala
100 105 110
Thr Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val Glu Val
115 120 125
Thr Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro Gln Ser
130 135 140
Pro Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro Leu Trp
145 150 155 160
Ser Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly Pro Ser
165 170 175
Thr Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser Arg Lys
180 185 190
Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala Arg Glu
195 200 205
Pro Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn Trp Gln
210 215 220
Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
225 230 235 240
Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu Tyr
245 250 255
Ile Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp
260 265 270
Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu Ala Ile
275 280 285
Ile Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu
290 295 300
Leu Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile Leu Gly
305 310 315 320
Asp Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn Tyr Leu
325 330 335
Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu
340 345 350
Trp Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val Leu His
355 360 365
His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro Pro Leu
370 375 380
His Glu Trp Val Leu Arg Glu Gly Glu Glu Gly Gly His His His His
385 390 395 400
His His His
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1212 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
ATGGATCCAA ACACTGTGTC AAGCTTTCAG GTAGATTGCT TTCTTTGGCA TGTCCGCAAA 60
CGAGTTGCAG ACCAAGAACT AGGTGATGCC CCATTCCTTG ATCGGCTTCG CCGAGATCAG 120
AAATCCCTAA GAGGAAGGGG CAGCACTCTT GGTCTGGACA TCGAGACAGC CACACGTGCT 180
GGAAAGCAGA TAGTGGAGCG GATTCTGAAA GAAGAATCCG ATGAGGCACT TAAAATGACC 240
ATGGATCTGG AACAGCGTAG TCAGCACTGC AAGCCTGAAG AAGGCCTTGA GGCCCGAGGA 300
GAGGCCCTGG GCCTGGTGGG TGCGCAGGCT CCTGCTACTG AGGAGCAGGA GGCTGCCTCC 360
TCCTCTTCTA CTCTAGTTGA AGTCACCCTG GGGGAGGTGC CTGCTGCCGA GTCACCAGAT 420
CCTCCCCAGA GTCCTCAGGG AGCCTCCAGC CTCCCCACTA CCATGAACTA CCCTCTCTGG 480
AGCCAATCCT ATGAGGACTC CAGCAACCAA GAAGAGGAGG GGCCAAGCAC CTTCCCTGAC 540
CTGGAGTCCG AGTTCCAAGC AGCACTCAGT AGGAAGGTGG CCGAATTGGT TCATTTTCTG 600
CTCCTCAAGT ATCGAGCCAG GGAGCCGGTC ACAAAGGCAG AAATGCTGGG GAGTGTCGTC 660
GGAAATTGGC AGTATTTCTT TCCTGTGATC TTCAGCAAAG CTTCCAGTTC CTTGCAGCTG 720
GTCTTTGGCA TCGAGCTGAT GGAAGTGGAC CCCATCGGCC ACTTGTACAT CTTTGCCACC 780
TGCCTGGGCC TCTCCTACGA TGGCCTGCTG GGTGACAATC AGATCATGCC CAAGGCAGGC 840
CTCCTGATAA TCGTCCTGGC CATAATCGCA AGAGAGGGCG ACTGTGCCCC TGAGGAGAAA 900
ATCTGGGAGG AGCTGAGTGT GTTAGAGGTG TTTGAGGGGA GGGAAGACAG TATCTTGGGG 960
GATCCCAAGA AGCTGCTCAC CCAACATTTC GTGCAGGAAA ACTACCTGGA GTACCGGCAG 1020
GTCCCCGGCA GTGATCCTGC ATGTTATGAA TTCCTGTGGG GTCCAAGGGC CCTCGTTGAA 1080
ACCAGCTATG TGAAAGTCCT GCACCATATG GTAAAGATCA GTGGAGGACC TCACATTTCC 1140
TACCCACCCC TGCATGAGTG GGTTTTGAGA GAGGGGGAAG AGGGCGGTCA TCACCATCAC 1200
CATCACCATT AA 1212
(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 445 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
Met Lys Gly Gly Ile Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys
1 5 10 15
Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr
20 25 30
Met Leu Ala Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp
35 40 45
Phe Asp Asn Ser Gly Glu Met Ala Thr Gly Trp Lys Lys Ile Ala Asp
50 55 60
Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala Met Lys Thr Gly Trp Val
65 70 75 80
Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Ala Lys Glu Gly Ala Met
85 90 95
Val Ser Asn Ala Phe Ile Gln Ser Ala Asp Gly Thr Gly Trp Tyr Tyr
100 105 110
Leu Lys Pro Asp Gly Thr Leu Ala Asp Arg Pro Glu Leu Asp Met Gly
115 120 125
Ser Leu Glu Gln Arg Ser Leu His Cys Lys Pro Glu Glu Ala Leu Glu
130 135 140
Ala Gln Gln Glu Ala Leu Gly Leu Val Cys Val Gln Ala Ala Thr Ser
145 150 155 160
Ser Ser Ser Pro Leu Val Leu Gly Thr Leu Glu Glu Val Pro Thr Ala
165 170 175
Gly Ser Thr Asp Pro Pro Gln Ser Pro Gln Gly Ala Ser Ala Phe Pro
180 185 190
Thr Thr Ile Asn Phe Thr Arg Gln Arg Gln Pro Ser Glu Gly Ser Ser
195 200 205
Ser Arg Glu Glu Glu Gly Pro Ser Thr Ser Cys Ile Leu Glu Ser Leu
210 215 220
Phe Arg Ala Val Ile Thr Lys Lys Val Ala Asp Leu Val Gly Phe Leu
225 230 235 240
Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu Met Leu
245 250 255
Glu Ser Val Ile Lys Asn Tyr Lys His Cys Phe Pro Glu Ile Phe Gly
260 265 270
Lys Ala Ser Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys Glu
275 280 285
Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly Leu
290 295 300
Ser Tyr Asp Gly Leu Leu Gly Asp Asn Gln Ile Met Pro Lys Thr Gly
305 310 315 320
Phe Leu Ile Ile Val Leu Val Met Ile Ala Met Glu Gly Gly His Ala
325 330 335
Pro Glu Glu Glu Ile Trp Glu Glu Leu Ser Val Met Glu Val Tyr Asp
340 345 350
Gly Arg Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln
355 360 365
Asp Leu Val Gln Glu Lys Tyr Leu Glu Tyr Arg Gln Val Pro Asp Ser
370 375 380
Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala Leu Ala Glu
385 390 395 400
Thr Ser Tyr Val Lys Val Leu Glu Tyr Val Ile Lys Val Ser Ala Arg
405 410 415
Val Arg Phe Phe Phe Pro Ser Leu Arg Glu Ala Ala Leu Arg Glu Glu
420 425 430
Glu Glu Gly Val Gly Gly His His His His His His His
435 440 445
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1338 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
ATGAAAGGGG GAATTGTACA TTCAGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60
AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120
CACACAGACG GCAACTGGTA CTGGTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180
AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240
AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGGT ATCAAATGCC 300
TTTATCCAGT CAGCGGACGG AACAGGCTGG TACTACCTCA AACCAGACGG AACACTGGCA 360
GACAGGCCAG AATTGGACAT GGGCTCTCTG GAACAGCGTA GTCTGCACTG CAAGCCTGAG 420
GAAGCCCTTG AGGCCCAACA AGAGGCCCTG GGCCTGGTGT GTGTGCAGGC TGCCACCTCC 480
TCCTCCTCTC CTCTGGTCCT GGGCACCCTG GAGGAGGTGC CCACTGCTGG GTCAACAGAT 540
CCTCCCCAGA GTCCTCAGGG AGCCTCCGCC TTTCCCACTA CCATCAACTT CACTCGACAG 600
AGGCAACCCA GTGAGGGTTC CAGCAGCCGT GAAGAGGAGG GGCCAAGCAC CTCTTGTATC 660
CTGGAGTCCT TGTTCCGAGC AGTAATCACT AAGAAGGTGG CTGATTTGGT TGGTTTTCTG 720
CTCCTCAAAT ATCGAGCCAG GGAGCCAGTC ACAAAGGCAG AAATGCTGGA GAGTGTCATC 780
AAAAATTACA AGCACTGTTT TCCTGAGATC TTCGGCAAAG CCTCTGAGTC CTTGCAGCTG 840
GTCTTTGGCA TTGACGTGAA GGAAGCAGAC CCCACCGGCC ACTCCTATGT CCTTGTCACC 900
TGCCTAGGTC TCTCCTATGA TGGCCTGCTG GGTGATAATC AGATCATGCC CAAGACAGGC 960
TTCCTGATAA TTGTCCTGGT CATGATTGCA ATGGAGGGCG GCCATGCTCC TGAGGAGGAA 1020
ATCTGGGAGG AGCTGAGTGT GATGGAGGTG TATGATGGGA GGGAGCACAG TGCCTATGGG 1080
GAGCCCAGGA AGCTGCTCAC CCAAGATTTG GTGCAGGAAA AGTACCTGGA GTACCGGCAG 1140
GTGCCGGACA GTGATCCCGC ACGCTATGAG TTCCTGTGGG GTCCAAGGGC CCTCGCTGAA 1200
ACCAGCTATG TGAAAGTCCT TGAGTATGTG ATCAAGGTCA GTGCAAGAGT TCGCTTTTTC 1260
TTCCCATCCC TGCGTGAAGC AGCTTTGAGA GAGGAGGAAG AGGGAGTCGG CGGTCATCAC 1320
CATCACCATC ACCATTAA 1338
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 454 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Met Lys Gly Gly Ile Val His Ser Asp Gly Ser Tyr Pro Lys Asp Lys
1 5 10 15
Phe Glu Lys Ile Asn Gly Thr Trp Tyr Tyr Phe Asp Ser Ser Gly Tyr
20 25 30
Met Leu Ala Asp Arg Trp Arg Lys His Thr Asp Gly Asn Trp Tyr Trp
35 40 45
Phe Asp Asn Ser Gly Glu Met Ala Thr Gly Trp Lys Lys Ile Ala Asp
50 55 60
Lys Trp Tyr Tyr Phe Asn Glu Glu Gly Ala Met Lys Thr Gly Trp Val
65 70 75 80
Lys Tyr Lys Asp Thr Trp Tyr Tyr Leu Asp Ala Lys Glu Gly Ala Met
85 90 95
Val Ser Asn Ala Phe Ile Gln Ser Ala Asp Gly Thr Gly Trp Tyr Tyr
100 105 110
Leu Lys Pro Asp Gly Thr Leu Ala Asp Arg Pro Glu Leu Ala Ser Met
115 120 125
Leu Asp Met Asp Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu
130 135 140
Gly Leu Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala
145 150 155 160
Pro Ala Thr Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val
165 170 175
Glu Val Thr Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro
180 185 190
Gln Ser Pro Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro
195 200 205
Leu Trp Ser Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly
210 215 220
Pro Ser Thr Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser
225 230 235 240
Arg Lys Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala
245 250 255
Arg Glu Pro Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn
260 265 270
Trp Gln Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu
275 280 285
Gln Leu Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His
290 295 300
Leu Tyr Ile Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu
305 310 315 320
Gly Asp Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu
325 330 335
Ala Ile Ile Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp
340 345 350
Glu Glu Leu Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile
355 360 365
Leu Gly Asp Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn
370 375 380
Tyr Leu Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu
385 390 395 400
Phe Leu Trp Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val
405 410 415
Leu His His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro
420 425 430
Pro Leu His Glu Trp Val Leu Arg Glu Gly Glu Glu Gly Gly His His
435 440 445
His His His His His
450
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1362 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
ATGAAAGGGG GAATTGTACA TTCAGACGGC TCTTATCCAA AAGACAAGTT TGAGAAAATC 60
AATGGCACTT GGTACTACTT TGACAGTTCA GGCTATATGC TTGCAGACCG CTGGAGGAAG 120
CACACAGACG GCAACTGGTA CTGGTTCGAC AACTCAGGCG AAATGGCTAC AGGCTGGAAG 180
AAAATCGCTG ATAAGTGGTA CTATTTCAAC GAAGAAGGTG CCATGAAGAC AGGCTGGGTC 240
AAGTACAAGG ACACTTGGTA CTACTTAGAC GCTAAAGAAG GCGCCATGGT ATCAAATGCC 300
TTTATCCAGT CAGCGGACGG AACAGGCTGG TACTACCTCA AACCAGACGG AACACTGGCA 360
GACAGGCCAG AATTGGCCAG CATGCTGGAC ATGGATCTGG AACAGCGTAG TCAGCACTGC 420
AAGCCTGAAG AAGGCCTTGA GGCCCGAGGA GAGGCCCTGG GCCTGGTGGG TGCGCAGGCT 480
CCTGCTACTG AGGAGCAGGA GGCTGCCTCC TCCTCTTCTA CTCTAGTTGA AGTCACCCTG 540
GGGGAGGTGC CTGCTGCCGA GTCACCAGAT CCTCCCCAGA GTCCTCAGGG AGCCTCCAGC 600
CTCCCCACTA CCATGAACTA CCCTCTCTGG AGCCAATCCT ATGAGGACTC CAGCAACCAA 660
GAAGAGGAGG GGCCAAGCAC CTTCCCTGAC CTGGAGTCTG AGTTCCAAGC AGCACTCAGT 720
AGGAAGGTGG CCAAGTTGGT TCATTTTCTG CTCCTCAAGT ATCGAGCCAG GGAGCCGGTC 780
ACAAAGGCAG AAATGCTGGG GAGTGTCGTC GGAAATTGGC AGTACTTCTT TCCTGTGATC 840
TTCAGCAAAG CTTCCGATTC CTTGCAGCTG GTCTTTGGCA TCGAGCTGAT GGAAGTGGAC 900
CCCATCGGCC ACGTGTACAT CTTTGCCACC TGCCTGGGCC TCTCCTACGA TGGCCTGCTG 960
GGTGACAATC AGATCATGCC CAAGACAGGC TTCCTGATAA TCATCCTGGC CATAATCGCA 1020
AAAGAGGGCG ACTGTGCCCC TGAGGAGAAA ATCTGGGAGG AGCTGAGTGT GTTAGAGGTG 1080
TTTGAGGGGA GGGAAGACAG TATCTTCGGG GATCCCAAGA AGCTGCTCAC CCAATATTTC 1140
GTGCAGGAAA ACTACCTGGA GTACCGGCAG GTCCCCGGCA GTGATCCTGC ATGCTATGAG 1200
TTCCTGTGGG GTCCAAGGGC CCTCATTGAA ACCAGCTATG TGAAAGTCCT GCACCATATG 1260
GTAAAGATCA GTGGAGGACC TCGCATTTCC TACCCACTCC TGCATGAGTG GGCTTTGAGA 1320
GAGGGGGAAG AGGGCGGTCA TCACCATCAC CATCACCATT AA 1362
B45126
- One -

权利要求:
Claims (20)
[1" claim-type="Currently amended] Tumor related antigen derivatives from the MAGE group.
[2" claim-type="Currently amended] The antigen of claim 1, wherein the antigen derivative is a MAGE protein linked with an immunological fusion partner or expression amplification partner.
[3" claim-type="Currently amended] The antigen of claim 1 or 2, wherein the antigen derivative comprises an affinity tag.
[4" claim-type="Currently amended] The antigen according to any one of claims 1 to 3, comprising derivatized free thiols.
[5" claim-type="Currently amended] The antigen of claim 4 which is a carboxyamide or carboxymethylated derivative.
[6" claim-type="Currently amended] The method according to any one of claims 2, 3, 4 and 5, wherein the fusion partner is Protein D or fragments thereof from Haemophilus influenza B, NS1 protein from fragments of influenza or fragments or streptococks. A protein characterized by Lyta or a fragment thereof from Curse pneumoniae.
[7" claim-type="Currently amended] The protein according to any one of claims 2, 3, 4 and 5, wherein the fusion partner is a lipidated form of Protein D or fragments thereof from Haemophilus influenza B.
[8" claim-type="Currently amended] The method according to any one of claims 1 to 7, wherein the MAGE protein is selected from the group MAGE A1, MAGE A2, MAGE A3, MAGE A4, MAGE A5, MAGE A6, MAGE A7, MAGE A8, MAGE A9, MAGE A10, MAGE A11, MAGE A12, MAGE B1, MAGE B2, MAGE B3 and MAGE B4, MAGE C1, MAGE C2.
[9" claim-type="Currently amended] Nucleic acid sequences encoding the proteins claimed herein.
[10" claim-type="Currently amended] The vector containing the nucleic acid of Claim 9.
[11" claim-type="Currently amended] A host transformed using the vector of claim 10.
[12" claim-type="Currently amended] A vaccine comprising a protein as claimed in claim 1 or a nucleic acid as claimed in claim 9.
[13" claim-type="Currently amended] 13. The vaccine of claim 12, further comprising an adjuvant and / or an immunostimulatory cytokine or chemokine.
[14" claim-type="Currently amended] The vaccine of claim 12 or 13, wherein the protein is in an oil-in-water or water-in-oil emulsion carrier.
[15" claim-type="Currently amended] The vaccine of claim 13 or 14, wherein the adjuvant comprises 3D-MPL, QS21 or CpG oligonucleotides.
[16" claim-type="Currently amended] 16. The vaccine of any one of claims 12-15, further comprising one or more antigens.
[17" claim-type="Currently amended] The vaccine according to any one of claims 12 to 16 for use in medicine.
[18" claim-type="Currently amended] Use of the claimed protein or nucleic acid in the claims for the manufacture of a vaccine for the treatment of a patient suffering from melanoma or other MAGE related tumor with immunotherapy.
[19" claim-type="Currently amended] A process for the purification of MAGE proteins or derivatives thereof comprising reducing disulfite bonds, blocking the obtained free thiol groups using blockers and subjecting the obtained derivatives to one or more chromatographic purification steps.
[20" claim-type="Currently amended] 20. A method of making a vaccine comprising purifying a MAGE protein or derivative thereof by the method of claim 19 and formulating the obtained protein as a vaccine.

类似技术:

---

公开号 | 公开日 | 专利标题

---

EP2280031B1|2015-04-15|Cancer antigens based on products of the tumor suppressor gene WT1

---

EP1511768B1|2007-04-11|Immunogenic compositions

---

JP4130359B2|2008-08-06|Compositions and methods for WT1-specific immunotherapy

---

US10239916B2|2019-03-26|Controlled modulation of amino acid side chain length of peptide antigens

---

KR100731820B1|2007-06-25|Novel methods for therapeutic vaccination

---

US7074898B2|2006-07-11|Compositions and methods for therapy and diagnosis of prostate cancer

---

AU2004282332B2|2010-05-20|Recombinant vaccines and use thereof

---

Bolhassani et al.2008|Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

---

EP0554344B1|1998-08-12|Pharmaceutical composition for the treatment or prevention of a malignant tumor

---

CN1227360C|2005-11-16|Tumor-associated antigen derivatives from MAGE family, and nucleic acid sequence encoding them

---

DE69827507T2|2006-03-09|Trimerizing module

---

US8535690B2|2013-09-17|Tumor specific animal proteins

---

EP1015596B2|2010-04-14|Fusion proteins comprising hiv-1 tat and/or nef proteins

---

US7262014B2|2007-08-28|Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

---

US9452204B2|2016-09-27|Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes

---

ES2719832T3|2019-07-16|Non-hemolytic LLO fusion proteins and uses thereof

---

JP5053497B2|2012-10-17|Compositions and methods for the treatment and diagnosis of breast cancer

---

Li et al.2006|Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy

---

JP2006515749A|2006-06-08|Compositions and methods for the treatment and diagnosis of prostate cancer

---

ES2326311T3|2009-10-07|Compositions and methods for specific immunotherapy with wt1.

---

US20160220652A1|2016-08-04|Methods of using recombinant listeria vaccine strains in diseaseimmunotherapy

---

JP2008214360A|2008-09-18|Immune response using composition containing stress protein

---

US8114414B2|2012-02-14|Compositions and methods for treatment of cervical cancer

---

EP1007551B1|2004-05-19|Vaccine against hpv

---

EP0975668B1|2006-05-17|MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA

同族专利:

---

公开号 | 公开日

---

BR9907691A|2000-11-14|

---

IL188875D0|2009-02-11|

---

AR018064A1|2001-10-31|

---

SI1584685T1|2011-07-29|

---

JP2002502604A|2002-01-29|

---

IL137442A|2008-04-13|

---

US20100209444A1|2010-08-19|

---

NO20091665L|2000-10-04|

---

DK1659178T3|2010-07-12|

---

CA2584482A1|1999-08-12|

---

ES2342416T3|2010-07-06|

---

SA1151B1|2006-08-20|

---

AT513042T|2011-07-15|

---

EP1659179A2|2006-05-24|

---

EP1584685B1|2011-04-13|

---

EP1659179A3|2007-01-17|

---

PL342852A1|2001-07-16|

---

CZ298347B6|2007-09-05|

---

CN1227360C|2005-11-16|

---

US20120269835A1|2012-10-25|

---

EP1053325A2|2000-11-22|

---

NO20003958D0|2000-08-04|

---

DK1584685T3|2011-07-11|

---

CN1295616A|2001-05-16|

---

WO1999040188A2|1999-08-12|

---

HK1083026A1|2011-12-09|

---

AT315088T|2006-02-15|

---

DE69929310T2|2006-08-03|

---

JP4768121B2|2011-09-07|

---

KR20060067977A|2006-06-20|

---

EP1053325B1|2006-01-04|

---

CY1110180T1|2015-01-14|

---

DK1659179T3|2011-10-10|

---

WO1999040188A3|1999-10-14|

---

ES2255248T3|2006-06-16|

---

NO20003958L|2000-10-04|

---

BR9907691B1|2011-05-31|

---

SI1659178T1|2010-07-30|

---

KR100824105B1|2008-04-21|

---

JP2009201510A|2009-09-10|

---

IL179010D0|2007-03-08|

---

EP1659179B1|2011-06-15|

---

EP1659178A2|2006-05-24|

---

HU0102639A3|2004-04-28|

---

IL188875A|2011-08-31|

---

CA2584482C|2012-03-27|

---

US8044183B2|2011-10-25|

---

CY1111831T1|2015-10-07|

---

AT505542T|2011-04-15|

---

US20100204458A1|2010-08-12|

---

AU2722099A|1999-08-23|

---

PT1584685E|2011-06-17|

---

DE69942214D1|2010-05-12|

---

HK1033838A1|2006-11-03|

---

DE69929310D1|2006-03-30|

---

CZ20002869A3|2001-01-17|

---

CA2319309A1|1999-08-12|

---

TR200002284T2|2000-11-21|

---

HK1093522A1|2010-09-17|

---

HK1093521A1|2011-12-09|

---

CZ298364B6|2007-09-05|

---

AU737337B2|2001-08-16|

---

DE69943359D1|2011-05-26|

---

US8097257B2|2012-01-17|

---

PT1053325E|2006-05-31|

---

NO328507B1|2010-03-08|

---

HU0102639A2|2001-11-28|

---

NO331719B1|2012-03-05|

---

EP1659178B1|2010-03-31|

---

CY1111672T1|2015-10-07|

---

AT462788T|2010-04-15|

---

DK1053325T3|2006-05-22|

---

HU228467B1|2013-03-28|

---

SI1659179T1|2011-10-28|

---

PT1659179E|2011-09-16|

---

NZ506086A|2003-01-31|

---

EP1584685A3|2005-12-07|

---

IL137442D0|2001-07-24|

---

US8597656B2|2013-12-03|

---

TWI238853B|2005-09-01|

---

EP1659178A3|2007-01-17|

---

KR100633212B1|2006-10-11|

---

PT1659178E|2010-06-28|

---

CA2319309C|2010-08-10|

---

SI1053325T1|2006-06-30|

---

EP1584685A2|2005-10-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1998-02-05|Priority to GBGB9802543.0A

---

1998-02-05|Priority to GB9802543.0

---

1998-02-06|Priority to GB9802650.3

---

1998-02-06|Priority to GBGB9802650.3A

---

1999-02-02|Application filed by 장 스테판느, 스미스클라인 비이참 바이오로지칼즈 에스.에이.

---

2001-05-15|Publication of KR20010040675A

---

2006-10-11|Application granted

---

2006-10-11|Publication of KR100633212B1

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB9802543.0A|GB9802543D0|1998-02-05|1998-02-05|Vaccine|

---

GB9802543.0|1998-02-05|

---

GB9802650.3|1998-02-06|

---

GBGB9802650.3A|GB9802650D0|1998-02-06|1998-02-06|Vaccine|